• WM-8014: Precision KAT6A Inhibitor for Cancer Biology Workfl

  2026-06-25

  WM-8014 stands out as a highly selective KAT6A inhibitor, enabling robust oncogene-induced senescence and cell cycle arrest assays without confounding cytotoxicity. This article delivers actionable protocols, advanced applications, and troubleshooting strategies for leveraging WM-8014 in next-generation epigenetic and cancer biology research.

• GSK J4 HCl in Epigenetic Regulation: JMJD3 Inhibitor Workflo

  2026-06-25

  GSK J4 HCl, a potent JMJD3 inhibitor from APExBIO, empowers researchers to precisely manipulate histone methylation in models of inflammation, immune modulation, and cancer. Leverage its unique cell-permeability, robust in vitro/in vivo activity, and evidence-backed workflows for reproducible, high-impact epigenetic research.

• EPZ5676: Precision DOT1L Inhibitor Workflows for Leukemia Re

  2026-06-24

  EPZ5676 offers exceptional potency and selectivity as a DOT1L inhibitor, enabling high-confidence dissection of H3K79 methylation roles in leukemia and beyond. This guide translates key mechanistic insights and published protocols into actionable workflows and troubleshooting strategies for maximizing the impact of your epigenetic assays.

• Mithramycin A: Anticancer Antibiotic for Targeted Research W

  2026-06-23

  Mithramycin A stands out as an anticancer antibiotic and precision tool for modulating gene expression in both leukemia research and advanced cardiac models. This article delivers hands-on workflow guidance, protocol optimization, and troubleshooting insights, translating the latest mechanistic discoveries into actionable steps for researchers.

• CHIR-99021 (CT99021): Selective GSK-3 Inhibition in Stem Cel

  2026-06-23

  CHIR-99021 (CT99021) is a potent, selective GSK-3α/β inhibitor that modulates Wnt/β-catenin signaling to maintain pluripotency and drive differentiation in stem cell models. Its application is supported by robust evidence for pathway selectivity and reproducibility. APExBIO provides validated CHIR-99021 for high-fidelity stem cell research workflows.

• Ademetionine (SAM): Applied Workflows for Methylation Resear

  2026-06-22

  S-Adenosylmethionine (Ademetionine) empowers precision in methylation assays spanning epigenetics, neurobiology, and hepatic disease modeling. Discover protocol-driven insights, troubleshooting, and recent innovations that maximize the reliability of APExBIO’s high-purity SAM in advanced experimental workflows.

• Qushi Huoxue Ointment Mitigates MASLD via Autophagy and Ferr

  2026-06-22

  This study reveals that Qushi Huoxue ointment (QSHXO) alleviates metabolic associated steatotic liver disease (MASLD) by simultaneously activating autophagy and inhibiting ferroptosis in a mouse model. These findings highlight new mechanistic insights into traditional Chinese medicine's role in addressing hepatic lipid accumulation and inflammation, offering translational relevance for metabolic liver disease research.

• N6-Methyl-dATP: Epigenetic Fidelity and AML Mechanism Insigh

  2026-06-21

  Explore the role of N6-Methyl-dATP in unraveling DNA replication fidelity and its unique value for acute myeloid leukemia (AML) research. This article delivers advanced mechanistic insight and practical assay guidance distinct from conventional workflows.

• Curcumol Disrupts Methionine Metabolism to Induce HSC Death

  2026-06-20

  This study demonstrates that curcumol induces autophagy-dependent death of hepatic stellate cells by disrupting methionine metabolism. Supplementation with S-adenosylmethionine (SAM) partially reverses these effects, highlighting the central role of methylation pathways in liver fibrosis and offering new mechanistic insight for antifibrotic strategies.

• I-BET-762: BET Inhibition at the Frontier of Ferroptosis & I

  2026-06-19

  Explore how the selective BET inhibitor I-BET-762 is reshaping translational research across cancer biology and inflammatory models, with new mechanistic insights into ferroptosis, ROS, and FSP1 regulation. This thought-leadership article blends mechanistic depth with actionable protocol guidance, and critically examines recent evidence positioning I-BET-762 as a cornerstone tool for next-generation epigenetic and cell death research.

• DiscoveryProbe Protease Inhibitor Library: Applied Workflows

  2026-06-19

  The DiscoveryProbe™ Protease Inhibitor Library empowers high-throughput, reproducible modulation of protease activity for advanced research in cancer, apoptosis, and infectious disease. This article details experimental workflows, troubleshooting tips, and protocol parameters that elevate screening outcomes beyond conventional libraries.

• A 83-01 (ALK-5 Inhibitor): Advanced Insights for Stem Cell a

  2026-06-18

  Explore how A 83-01, a potent ALK-5 inhibitor, is revolutionizing TGF-β signaling pathway studies with advanced applications in stem cell biology and hepatocyte stemness. This guide provides unique mechanistic insights and protocol strategies beyond standard organoid research.

• mRNA-LNP Programming of CAR Macrophages for Peritoneal Tumor

  2026-06-18

  This study introduces a macrophage-targeted mRNA lipid nanoparticle (mRNA-LNP) platform to reprogram macrophages into tailored CAR-Ms directly in the peritoneal cavity. The approach systematically evaluates CAR intracellular domain design, reveals mechanisms of immune activation and tumor microenvironment modulation, and demonstrates synergy with immune checkpoint inhibitors, offering new translational strategies against peritoneal metastases.

• 1-methyl Adenosine in RNA Modification and Biomarker Researc

  2026-06-17

  1-methyl Adenosine (1-methyl Ado) is a modified nucleoside pivotal in RNA modification research and biomarker discovery. The compound serves as a sensitive readout of RNA catabolism and is quantifiable by advanced UHPLC-MS/MS, supporting its role in cancer metabolism studies and disease diagnostics.

• LG 101506: Advancing RXR Modulation in Immuno-Oncology Resea

  2026-06-17

  This thought-leadership article explores how LG 101506, a high-purity RXR modulator from APExBIO, empowers translational researchers to unravel nuclear receptor signaling mechanisms that underpin immune resistance in cancer. By integrating mechanistic insight with strategic guidance, we highlight emerging approaches for targeting RXR pathways—particularly in the context of immune checkpoint biology and metabolism regulation—while referencing recent advances in triple-negative breast cancer (TNBC) immunotherapy. The article differentiates itself from typical product pages by bridging robust chemical biology with practical workflow recommendations and a forward-looking perspective on translational impact.

11605 records 5/774 page Previous Next 12345 下5页 Last page